1 week Ago By ABMN Staff
Wellington Management Group LLP reduced its stake in Zymeworks Inc. ( NYSE:ZYME – Free Report ) by 9.9% in the fourth quarter, HoldingsChannel reports.
The institutional investor owned 219,098 shares of the company’s stock after selling 24,091 shares during the quarter. Wellington Management Group LLP’s holdings in Zymeworks were worth $3,208,000 as of its most recent SEC filing. Other large investors have also bought and sold shares of the company.
Charles Schwab Investment Management Inc. raised its holdings in shares of Zymeworks by 0.5% in the third quarter.
Charles Schwab Investment Management Inc. now owns 132,798 shares of the company’s stock valued at $1,667,000 after purchasing an additional 650 shares during the last quarter. China Universal Asset Management Co.
Ltd. increased its stake in Zymeworks by 6.9% in the 4th quarter.
China Universal Asset Management Co. Ltd. now owns 14,605 shares of the company’s stock valued at $214,000 after buying an additional 940 shares during the last quarter.
FMR LLC lifted its position in shares of Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after buying an additional 1,525 shares in the last quarter.
Stifel Financial Corp boosted its stake in shares of Zymeworks by 2.1% in the 3rd quarter. Stifel Financial Corp now owns 73,654 shares of the company’s stock worth $924,000 after buying an additional 1,540 shares during the last quarter.
Finally, Teacher Retirement System of Texas grew its holdings in shares of Zymeworks by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 13,743 shares of the company’s stock valued at $201,000 after acquiring an additional 2,216 shares in the last quarter.
92.89% of the stock is currently owned by institutional investors. Zymeworks Stock Up 12.
6 % NYSE ZYME opened at $10.63 on Friday. The firm has a market cap of $739.
60 million, a P/E ratio of -7.09 and a beta of 1.18.
The company’s 50 day moving average is $12.68 and its 200-day moving average is $13.57.
Zymeworks Inc. has a 12-month low of $7.97 and a 12-month high of $17.
70. Insider Activity at Zymeworks Wall Street Analysts Forecast Growth A number of analysts recently commented on the company. Citigroup lifted their price target on Zymeworks from $18.
00 to $19.00 and gave the stock a “buy” rating in a report on Friday, March 7th. JPMorgan Chase & Co.
raised shares of Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 price target on the stock in a report on Monday, December 16th. Lifesci Capital started coverage on shares of Zymeworks in a report on Tuesday, March 11th.
They set an “outperform” rating and a $30.00 price objective for the company. HC Wainwright boosted their target price on shares of Zymeworks from $12.
00 to $13.00 and gave the company a “neutral” rating in a research note on Monday, March 10th. Finally, Wells Fargo & Company raised their price target on shares of Zymeworks from $12.
00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 19th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock.
According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $21.00.
Read Our Latest Research Report on ZYME Zymeworks Company Profile ( Free Report ) Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. Recommended Stories Want to see what other hedge funds are holding ZYME? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Zymeworks Inc. ( NYSE:ZYME – Free Report ). Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.
com's FREE daily email newsletter ..
